This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Latil, A. Articles by Vidaud, M. Search for Related Content PubMed PubMed Citation Articles by Latil, A. Articles by Vidaud, M.

Evaluation of Androgen, Estrogen (ER and ERß), and Progesterone Receptor Expression in Human Prostate Cancer by Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction Assays

CeRePP, Université Paris VII, F-91000 Evry [A. L., P. B., O. C.]; Laboratoire de Génétique Moléculaire, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, F-75006 Paris [I. B., D. V., M. V.]; Département d’Urologie, Université Paris VII, Hôpital Saint-Louis, F-75010 Paris [O. C.]; Institut Universitaire de France, F-75005 Paris [O. C.]; and Laboratoire d’Oncogénétique, Centre René Huguenin, F-92210 St. Cloud [I. B., R. L.], France

Steroid hormones can have profound effects on prostate tumor development making it important to define steroid receptor expression in prostate tissues. For this purpose, androgen receptor (AR) and estrogen receptor (ER and ERß) expression was quantified in 12 clinically localized and 11 hormone-refractory sporadic prostate tumors, using real-time quantitative reverse transcription-PCR assays. To gain more insight into hormone-responsiveness, estrogen-regulated progesterone receptor (PGR) and androgen-regulated prostatic acid phosphatase (PAP) mRNA levels were also quantified. There is a decrease in expression of ERß in both clinically localized and hormone-refractory tumors relative to normal prostate tissues. Moreover, hormone-refractory tumors display a decreased expression of ER and an increased expression of AR. There is a positive association between ER, ERß, and PGR expression (P < 0.0001) and a negative association between AR and the androgen-regulated gene PAP expression in hormone-refractory tumors. Taken together, these data indicate that, although increased expression of the AR gene might play a key role in endocrine treatment failure, it cannot be considered as the sole actor of this unresolved dilemma, and abnormalities in ER and/or ERß expression may also modulate the growth response of prostate cancer to hormone withdrawal. Our results also suggest that ER and ERß expression status could be used to identify advanced prostate tumor patients who may respond to antiestrogen therapy.

This article has been cited by other articles:

				K. K. Waltering, M. A. Helenius, B. Sahu, V. Manni, M. J. Linja, O. A. Janne, and T. Visakorpi Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens Cancer Res., October 15, 2009; 69(20): 8141 - 8149. [Abstract] [Full Text] [PDF]

				N. Nicolaiew, G. Cancel-Tassin, A. R. Azzouzi, B. L. Grand, P. Mangin, L. Cormier, G. Fournier, J.-P. Giordanella, M. Pouchard, J.-L. Escary, et al. Association between estrogen and androgen receptor genes and prostate cancer risk Eur. J. Endocrinol., January 1, 2009; 160(1): 101 - 106. [Abstract] [Full Text] [PDF]

				G. Fromont, M. Yacoub, A. Valeri, P. Mangin, G. Vallancien, G. Cancel-Tassin, and O. Cussenot Differential Expression of Genes Related to Androgen and Estrogen Metabolism in Hereditary versus Sporadic Prostate Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1505 - 1509. [Abstract] [Full Text] [PDF]

				M. A. Cho, M. K. Lee, K.-H. Nam, W. Y. Chung, C. S. Park, J. H. Lee, T. Noh, W. I. Yang, Y. Rhee, S.-K. Lim, et al. Expression and role of estrogen receptor {alpha} and {beta} in medullary thyroid carcinoma: different roles in cancer growth and apoptosis J. Endocrinol., November 1, 2007; 195(2): 255 - 263. [Abstract] [Full Text] [PDF]

				Y.-C. Chen, P. Kraft, P. Bretsky, S. Ketkar, D. J. Hunter, D. Albanes, D. Altshuler, G. Andriole, C. D. Berg, H. Boeing, et al. Sequence Variants of Estrogen Receptor {beta} and Risk of Prostate Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1973 - 1981. [Abstract] [Full Text] [PDF]

				M. Stettner, S. Kaulfuss, P. Burfeind, S. Schweyer, A. Strauss, R.-H. Ringert, and P. Thelen The relevance of estrogen receptor-{beta} expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment Mol. Cancer Ther., October 1, 2007; 6(10): 2626 - 2633. [Abstract] [Full Text] [PDF]

				D. A. Benitez, E. Pozo-Guisado, A. Alvarez-Barrientos, P. M. Fernandez-Salguero, and E. A. Castellon Mechanisms Involved in Resveratrol-Induced Apoptosis and Cell Cycle Arrest in Prostate Cancer-Derived Cell Lines J Androl, March 1, 2007; 28(2): 282 - 293. [Abstract] [Full Text] [PDF]

				R. A. Miksad, G. Bubley, P. Church, M. Sanda, N. Rofsky, I. Kaplan, and A. Cooper Prostate Cancer in a Transgender Woman 41 Years After Initiation of Feminization. JAMA, November 15, 2006; 296(19): 2316 - 2317. [Full Text] [PDF]

				H. Le, J. T. Arnold, K. K. McFann, and M. R. Blackman DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E952 - E960. [Abstract] [Full Text] [PDF]

				K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF]

				M. Zaitseva, B. J. Vollenhoven, and P. A.W. Rogers In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells Mol. Hum. Reprod., March 1, 2006; 12(3): 187 - 207. [Abstract] [Full Text] [PDF]

				C. Lagresle-Peyrou, F. Yates, M. Malassis-Seris, C. Hue, E. Morillon, A. Garrigue, A. Liu, P. Hajdari, D. Stockholm, O. Danos, et al. Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity Blood, January 1, 2006; 107(1): 63 - 72. [Abstract] [Full Text] [PDF]

				X. Liao, S. Tang, J. B. Thrasher, T. L. Griebling, and B. Li Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer Mol. Cancer Ther., April 1, 2005; 4(4): 505 - 515. [Abstract] [Full Text] [PDF]

				J. T. Arnold, H. Le, K. K. McFann, and M. R. Blackman Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E573 - E584. [Abstract] [Full Text] [PDF]

				A Bardin, N Boulle, G Lazennec, F Vignon, and P Pujol Loss of ER{beta} expression as a common step in estrogen-dependent tumor progression Endocr. Relat. Cancer, September 1, 2004; 11(3): 537 - 551. [Abstract] [Full Text] [PDF]

				A. Latil, I. Bieche, L. Chene, I. Laurendeau, P. Berthon, O. Cussenot, and M. Vidaud Gene Expression Profiling in Clinically Localized Prostate Cancer: A Four-Gene Expression Model Predicts Clinical Behavior Clin. Cancer Res., November 15, 2003; 9(15): 5477 - 5485. [Abstract] [Full Text] [PDF]

				M. N. Szentirmay, H.-X. Yang, S. A. Pawar, C. Vinson, and M. Sawadogo The IGF2 Receptor Is a USF2-specific Target in Nontumorigenic Mammary Epithelial Cells but Not in Breast Cancer Cells J. Biol. Chem., September 26, 2003; 278(39): 37231 - 37240. [Abstract] [Full Text] [PDF]

				P. Harkonen, S. Torn, R. Kurkela, K. Porvari, A. Pulkka, A. Lindfors, V. Isomaa, and P. Vihko Sex Hormone Metabolism in Prostate Cancer Cells during Transition to an Androgen-Independent State J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 705 - 712. [Abstract] [Full Text] [PDF]

				S. Godoy-Tundidor, A. Hobisch, K. Pfeil, G. Bartsch, and Z. Culig Acquisition of Agonistic Properties of Nonsteroidal Antiandrogens after Treatment with Oncostatin M in Prostate Cancer Cells Clin. Cancer Res., July 1, 2002; 8(7): 2356 - 2361. [Abstract] [Full Text] [PDF]

				V Speirs, G P Skliris, S E Burdall, and P J Carder Distinct expression patterns of ER{alpha} and ER{beta} in normal human mammary gland J. Clin. Pathol., May 1, 2002; 55(5): 371 - 374. [Abstract] [Full Text] [PDF]

				D. T. Solum and R. J. Handa Estrogen Regulates the Development of Brain-Derived Neurotrophic Factor mRNA and Protein in the Rat Hippocampus J. Neurosci., April 1, 2002; 22(7): 2650 - 2659. [Abstract] [Full Text] [PDF]

				E. Corey, J. E. Quinn, M. J. Emond, K. R. Buhler, L. G. Brown, and R. L. Vessella Inhibition of Androgen-independent Growth of Prostate Cancer Xenografts by 17{beta}-Estradiol Clin. Cancer Res., April 1, 2002; 8(4): 1003 - 1007. [Abstract] [Full Text] [PDF]

				L. G. Horvath, S. M. Henshall, C-S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O'Neill, et al. Frequent Loss of Estrogen Receptor-{beta} Expression in Prostate Cancer Cancer Res., July 1, 2001; 61(14): 5331 - 5335. [Abstract] [Full Text] [PDF]

				S. Signoretti and M. Loda Estrogen Receptor {beta} in Prostate Cancer : Brake Pedal or Accelerator? Am. J. Pathol., July 1, 2001; 159(1): 13 - 16. [Full Text] [PDF]